A Phase 1 Open-Label Study of PF-07985045 as A Single-Agent and in Combination With Other Anti-Cancer Agents in Participants With Advanced Solid Tumors
Latest Information Update: 07 Feb 2025
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Cetuximab (Primary) ; Cisplatin (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Gemcitabine (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; PF 07985045 (Primary) ; PF-07284892 (Primary) ; Sasanlimab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 04 Feb 2025 Planned number of patients changed from 230 to 190.
- 04 Feb 2025 Planned End Date changed from 2 Jan 2029 to 29 Jan 2029.
- 04 Feb 2025 Planned primary completion date changed from 3 Jan 2028 to 30 Jan 2028.